AACR: Markers Hint at Who Cancer Treatments Could Help
Meeting at cancer conference discusses possible role of TIMP-1, Trim62, CYP2D6 phenotype
FRIDAY, Nov. 20 (HealthDay News) -- Several abstracts involving potential biomarkers of prognosis in cancer treatment were presented at a press briefing Nov. 18 at the American Association for Cancer Research -- National Cancer Institute -- European Organisation for Research and Treatment of Cancer International Conference, "Molecular Targets and Cancer Therapeutics," held from Nov. 15 to 19 in Boston.
In one study utilizing 59 patients from the placebo group in a phase III trial for sorafenib in renal cell carcinoma, the biomarker TIMP-1 was found to be independently prognostic for survival. In another study, researchers identified a role of a novel protein, Trim62, in HER2-positive breast cancers. When Trim62 levels were reduced in these cells, cytoplasmic p27 shifted to the nucleus, and cell proliferation ceased. In addition, Trim62 levels appeared to have an inverse relationship with cells' sensitivity to lapatinib.
Researchers from Erasmus MC in Rotterdam, Netherlands, discussed another study involving 99 women with hormone receptor positive breast cancer who received tamoxifen to assess potential effects of CYP2D6 predicted phenotype. Women with extensive or intermediate metabolizer phenotypes had significantly better overall survival than the poor metabolizers.
"Our study found that, for women with hormone receptor positive metastatic breast cancer, CYP2D6 phenotype, as derived from both genotype information and co-medication use, is an important predictor of treatment outcomes associated with tamoxifen," researcher Laureen Lammers said in a prepared statement.